Splicing deregulation, microRNA and notch aberrations: fighting the three-headed dog to overcome drug resistance in malignant mesothelioma
- 4 March 2022
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 15 (3) , 305-322
Abstract
Malignant mesothelioma (MMe) is an aggressive rare cancer of the mesothelium, associated with asbestos exposure. MMe is currently an incurable disease at all stages mainly due to resistance to trea...Keywords
Funding Information
- Cancer Center Amsterdam (Foundation grant 2015)
- Italian Association for Cancer Research (2020-24444)
- Italian Ministry of Education, University and Research
- Mesothelioma Applied Research Foundation
- National Science Centre of Poland (2018/31/B/NZ7/02909)
- IDUB (664/256/62-0212)
- European Cooperation in Science and Technology
This publication has 166 references indexed in Scilit:
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility studyThe Lancet Oncology, 2011
- Onconase mediated NFKβ downregulation in malignant pleural mesotheliomaOncogene, 2011
- Notch signaling: Emerging molecular targets for cancer therapyBiochemical Pharmacology, 2010
- Downregulated microRNAs in the differential diagnosis of malignant pleural mesotheliomaInternational Journal of Cancer, 2010
- The Canonical Notch Signaling Pathway: Unfolding the Activation MechanismCell, 2009
- Mesothelioma Epidemiology, Carcinogenesis, and PathogenesisCurrent Treatment Options in Oncology, 2008
- Mesothelin targeted cancer immunotherapyEuropean Journal of Cancer, 2008
- Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemiaNature Medicine, 2007
- The MicroRNA miR-124 Promotes Neuronal Differentiation by Triggering Brain-Specific Alternative Pre-mRNA SplicingMolecular Cell, 2007